BioSpace News Archive

BRILINTA reduced bleeding vs dual therapy in high-risk coronary patients in sub-analyses from Phase IV TWILIGHT trial

March 30, 2020 13:23 UTC FDA Approves Next-Generation ZOLL ® TherOx System for Widowmaker Heart Attack Patients First and Only Treatment to Reduce Heart Muscle Damage Following Angioplasty and Stenting CHELMSFORD, Mass.--( BUSINESS WIRE )-- ZOLL ® Medical Corporation, an Asahi Kasei Group company that manufactures medical devices and related software solutions, announced today it has received U.S. Food and Drug Administration (FDA) approval of the second-generation Ther

Todos expands rights to include Asian countries and to include PCR test kits Corona Diagnostics JV with Emerald Organic responsible for commercialization Dr. Joseph Wee, CEO of Todos Singapore, will lead Asian commercialization effort REHOVOT, Israel and New York, NY, March 30, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Todos Medical Ltd. (OTCQB: TOMDF), a pre-commercial stage in-vitro-diagnostics company focused on the development of blood tests for the early detection of cancer

Technopath Clinical Diagnostics today announced that Northwell Health, New York State’s largest healthcare provider with 23 hospitals and nearly 800 outpatient facilities, is minimizing the risk of spreading COVID-19 by adopting Technopath’s technology platform that safely neutralizes infectious medical waste.

- Total 2020 Charitable Grants to Date Approach $13 Million, Including More than $3 million Devoted to Mental Health -

Nuvo Group, a private company with a bold ambition to reinvent pregnancy care for the 21st century, today announced that it has received clearance from the U.S. Food & Drug Administration (“FDA”) to market INVU™, a prescription-initiated, protocol-driven remote monitoring platform that offers measurements of fetal and maternal heart rate via a wireless, self-administered INVU sensor band.

Medtronic plc (NYSE:MDT) today announced positive results of the Onyx ONE Clear Study that evaluated Resolute Onyx DES in high bleeding risk (HBR) patients with one-month dual antiplatelet therapy (DAPT) in the United States and Japan.

Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) proudly announced that the company’s subsidiary Olaregen Therapeutics’ wound conforming matrix, Excellagen, has been awarded a Blanket Purchase Agreement (BPA) contract from the National Strategic Acquisition Center (SAC) through the efforts of AvMedical, Olaregen’s Small Disabled Veteran Owned Small Distributor (SDVOSD) partner.

Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), today announced that it has entered into definitive agreements with several healthcare-focused institutional investors for the purchase and sale of 1,275,000 shares of Bellerophon’s common stock, at a purchase price of $12.00 per share, in a registered direct offering priced at-the-market under Nasdaq rules.

Fractyl Laboratories Inc. (Fractyl) today announced clinical data that elucidate the mechanisms behind the beneficial effects and significant improvements in metabolic disease parameters for type 2 diabetes patients after one Revita® duodenal mucosal resurfacing (DMR) treatment.